linjc16/ctgov huggingface dataset:
Prognostic Value of Lactate Levels in Patients With STEMI Undergoing Primary PCI

Study Overview
=================
Brief Summary
-----------------
To assess the prognostic value of systemic arterial lactate levels in patients with ST segment elevation myocardial infarction undergoing primary PCI and correlate with the results of primary PCI and 30 days MACE follow up.

Detailed Description
-----------------
Study Population: STEMI patients treated with primary PCI. Study period: over 6 months. Sample Size: 300 patients. All patients received the standard care for acute STEMI patients which is the primary percutaneous intervention in addition to medications. Hyperlactemia is defined as elevated lactic acid level in the blood. The normal blood lactate level is (0.5-1 mmol/L). All subjects were subjected to Careful history taking Full cardiac examination Investigations include: 12 lead surface ECG. Lactate level and full labs Pre-discharge echocardiography Peri-procedural details of primary PCI the investigators assessed the relation between hyperlactemia and coronary flow, peak cardiac enzymes, hemodynamic parameters and MACE in 30 days follow up

Official Title
-----------------
Prognostic Value of Systemic Arterial Lactate Levels in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Conditions
-----------------
STEMI

Intervention / Treatment
-----------------
* Diagnostic Test: arterial lactate level


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with ST-segment elevation myocardial infarction for the first time. Patients undergoing primary PCI. Adult patients ≥ 18 years old. Exclusion criteria: Hemodynamically unstable patients. Patients with renal impairment (creatinine clearance < 30 ml/min). Patients who developed flow limiting coronary dissection or mechanical complication during the procedure. Patients presenting > 24 hours after symptoms onset.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: arterial lactate level|an arterial lactate level measured from arterial sample from STEMI patients|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse caediac events | we follow up occurrence of death, reinfarction, repeated hospitalization and new onset heart failure | 30 days |
Inflammatory Markers in Patients With Active Migraine Headaches

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether C-Reactive Protein (CRP) is elevated in patients with active migraine headaches. Secondary goal is to determine whether other inflammatory markers, such as Calcitonin Gene Peptide (CGRP), Vasoactive Intestinal Polypeptide (VIP) or Substance P (SP) are elevated in patients having a migraine headache.

Detailed Description
-----------------
A random selection of patients both male and female from a primary care practice with a diagnosis of having migraine headaches will be enrolled. Thirty (30) patients will be recruited mainly from the primary care practice. Recruitment will include males and females aged 21-65. The patients who meet the inclusion criteria will be enrolled. The patients who do not have migraine headaches will also be enrolled and function as controls. Non-migraine patients will meet inclusion criteria 1, 2 and 3 and all of the exclusion criteria.

Official Title
-----------------
Does Migraine As A Partly Inflammatory Disease Increase The Inflammatory Markers Of The Patient When Actively Having a Migraine?

Conditions
-----------------
Migraine

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must sign a written informed consent. Enrollment population would include males and females 21 years of age to 65 years of age. Non-migraine subjects will be allowed in the control group Have episodic migraine headaches Patients to satisfy the diagnosis of migraine headaches with aura, without aura or mixed. Must be able to differentiate migraine headaches from other headaches Exclusion Criteria: Any medical condition in the opinion of the investigator that would make the subject unsuitable for enrollment. Basilar or hemiplegic migraine headaches. Pregnant woman or a nursing mother History (within 1 year) or current evidence of drug or alcohol abuse. More than 15 migraine headaches per month Chronic daily headaches Chronic use of NSAIDs Current participation in a research study or within the last 30 days.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Inflammatory Markers, Migraine
Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy

Study Overview
=================
Brief Summary
-----------------
The aim is to identify in patients with brain metastases the predictive factors of overall survival, survival without local recurrence and survival with progression-free brain metastases after complementary whole brain radiotherapy.

Official Title
-----------------
Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy

Conditions
-----------------
Brain Metastasis

Intervention / Treatment
-----------------
* Radiation: whole brain radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with one to three brain metastases treated in our department with hypofractionated stereotactic radiotherapy (SRT) from March 2008 to February 2013. Exclusion Criteria: A patient record captured after February 2013.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: whole brain radiotherapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 72 months |
Services Mapping Among Older Adults With Hip Fracture

Study Overview
=================
Brief Summary
-----------------
Hip fracture is a osteoporosis-related fracture with higher mortality, and is a major public health issue in China. The British Orthopedic Association and the British Geriatric Society have published the UK Blue Book, which summarizes current evidence and best practice in the hip fracture care and secondary prevention, but this kind of standardized practice in hip fracture care is not yet existed in China. The Blue Book standards will be used as the most contemporary evidence-based guidelines for management of hip fracture.This study is to prospectively examine the barriers and facilitators in the current management of hospital in China by comparing the Blue Book standards.

Official Title
-----------------
Multicenter Prospective Observational Study in Hip Fracture Among Older Adults

Conditions
-----------------
Hip Fractures

Intervention / Treatment
-----------------
* Procedure: Hip Fracture Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults aged 65 years old or over; Hip fracture with X-ray-confirmed femoral neck, trochanteric or sub-trochanteric fracture; Within 21 days of a hip fracture; Willingness to sign informed consent form; Exclusion Criteria: Patients with pathological fractures; With terminal malignancies.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hip Fracture<br> | Procedure: Hip Fracture Surgery<br>* Hip Fracture Surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operative administration within 48 hours | The proportion of patients who are operated within 48 hours in the past one year | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A&E Admission within 4 hours | The proportion of patients who admit to orthopaedic ward from A&E within 4 hours in the past one year | One year | 
| The Incidence of Pressure Ulcer | The incidence of pressure ulcer in the past one year via nurses provide assessment | One year | 
| The Proportion of Patients Who Receive Geriatrician Assessment | The proportion of patients who receive the assessment of geriatricians in the past one year | One year | 
| The Proportion of Patients Who Receive Osteoporosis Assessment and Treatment | The proportion of patients who receive osteoporosis assessment and treatment the hospital provided in the past one year | One year | 
| The Proportion of Patients Who Receive Specialist Falls Assessment | The proportion of patients who receive specialist falls assessment in the past one year | One year |
The Effect of Rectal and Sublingual Misoprostol Administration in Postpartum or Intrapartum Haemorrhage at Elective Caesarean Delivery: a Randomized Controlled Trial

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesis in this study is that administration of rectal and sublingual misoprostol decreases intrapartum and postpartum haemorrhage.

Conditions
-----------------
ıntrapartum Haemorrhage, Postpartum Haemorrhage

Intervention / Treatment
-----------------
* Drug: Misoprostol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: live and singleton pregnancy Elective caesarean Gestational week greater than 37 weeks patient between 18-44 year old Exclusion Criteria: -multiple pregnancy Preeclampsia Gestational diabetes Macrosomia Oligohidraamnıos Polihidraamnıos Myoma Morbid obesity Coagulatıon defect (such as HELLP syndrome)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: sublingual<br>400 microgram mısoprostol will be administered sublıngually before elective caesarean | Drug: Misoprostol<br> <br> |
| Placebo Comparator: rectal<br>rectal 600 mgr misoprostol will be administered | Drug: Misoprostol<br> <br> |
| No Intervention: synpitan<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postpartum Haemorrhage |  | postpartum 24 hour |
Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase III trial to compare cisplatin and etoposide with no chemotherapy in treating patients who have stage I, stage II, or stage IIIA non-small cell lung cancer that has been surgically removed.

Detailed Description
-----------------
OBJECTIVES: Assess the efficacy of the combination of cisplatin and etoposide after radical surgery in prolonging the relapse free and overall survival for stages I, II, and IIIA non-small cell lung cancer. OUTLINE: This a randomized study (treatment vs no treatment). Patients are stratified according to sex and to stage of disease (I vs II vs IIIA). Patient receives cisplatin and etoposide on days 1-3, every 28 days, for 3 cycles. Patient may receive radiation therapy after surgery at the discretion of the physician. PROJECTED ACCRUAL: Approximately 750 patients will be accrued over 3 years.

Official Title
-----------------
Adjuvant Treatment of Non Small Cell Lung Cancer

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Drug: cisplatin
* Drug: etoposide
* Procedure: adjuvant therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Histologically proven stage I, II, or IIIA non-small cell lung cancer after radical surgery No evidence of lymphonodal enlargement during postsurgical chest CT scan PATIENT CHARACTERISTICS: Age: 70 and under Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Not specified Renal: Creatinine no greater than 1.5 times the upper limit of normal Pulmonary: FEV1 at least 1 liter Other: Less than 10% weight loss in the past 3 months No prior malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Radical surgery required

Ages Eligible for Study
-----------------
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: cisplatin|nan|
|Drug: etoposide|nan|
|Procedure: adjuvant therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage I non-small cell lung cancer, stage II non-small cell lung cancer, stage IIIA non-small cell lung cancer
Lenalidomide Based Immunotherapy in the Treatment of DLBCL

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate the efficacy related molecular biomarker of Lenalidomide plus RCHOP or RICE in the treatment of de novo or Refractory and Relapsed DLBCL patients

Official Title
-----------------
Lenalidomide Based Immunotherapy Efficacy Related Molecular Biomarker in Diffuse Large B-cell Lymphoma

Conditions
-----------------
Diffuse Large B Cell Lymphoma

Intervention / Treatment
-----------------
* Drug: Lenalidomide 25mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically diagnosed as diffuse large b-cell lymphoma and may provide a desirable lymph node tissue sample (10 paraffin sections or rolls) or lymph node biopsy sample (15 paraffin sections or rolls) Previously treated with Lenalidomide plus RCHOP regimen in de novo DLBCL or Lenalidomide plus RICE regimen in relapse refractory DLBCL. No history of stem cell transplantation. Written informed consent. Exclusion Criteria: Chemotherapy or large field radiotherapy within 3 weeks prior to entering the study. Clinically significant active infection. Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule. Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures. Subject has ≥grade 2 peripheral neuropathy or grade 1 with pain within 14 days before enrollment. Patients who are pregnant or breast-feeding. HIV infection.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lenalidomide 25mg|Lenalidomide 25mg/d PO d1-10 Plus Rituximab 375 mg/m2 IV d1, Cyclophosphamide 750mg/m2 IV d2, Doxorubicin 50mg/m2 IV d2, Vincristine 1.4 mg/m2 IV d2, Prednisone 60 mg/m2 PO d2-6 OR Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5*[GFR(ml/min)+25]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3,|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete response rate |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival rate |  | 1 year | 
| Overall survival rate |  | 1 year | 
| Overall response rate |  | 12 weeks |
Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis

Study Overview
=================
Brief Summary
-----------------
The adjunctive use of systemically administered antibiotics has been shown to provide a better clinical outcome, particularly in terms of probing depth (PD) reduction and attachment-level gain than SRP in subjects with Aggressive Periodontitis. The overall objective of this study is to evaluate the clinical and microbiological efficacy of moxifloxacin as an adjunct to scaling and root planing versus scaling and root planing over placebo in the treatment of aggressive periodontitis.

Official Title
-----------------
Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis: Double-blind Controlled Clinical Trial

Conditions
-----------------
Aggressive Periodontitis

Intervention / Treatment
-----------------
* Other: scaling and systemic moxifloxacin
* Other: scaling and root planing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: under 30 years old and systemically healthy, with at least 20 teeth present. Be willing to participate in the study which is corroborated by signing the informed consent form. Commit to attend post-therapeutic controls and stop drinking alcohol during the time of ingestion of antibiotics. Exclusion Criteria: Subjects in whom are contraindicated or with hypersensitivity to quinolones - Subjects who have undergone periodontal, surgical or mechanical antibiotic therapy six months before the start of the study according to interrogation. Women in pregnancy or lactation, corroborated with previous medical history and medical consultation.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: scaling and root planing<br>scaling and root planing | Other: scaling and root planing<br>* scaling and root planing<br>|
| Experimental: scaling and systemic moxifloxacin<br>scaling and root planing combined with systemic moxifloxacin | Other: scaling and systemic moxifloxacin<br>* scaling and root planing (SRP) combined with systemic moxifloxacin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| probing depth |  | six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical attachment level and probing depth |  | 6 moths | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aggressive Periodontitis, antimicrobial(s), microbiology
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)

Study Overview
=================
Brief Summary
-----------------
This study will determine if ZOSTAVAX™ is safe, tolerable, and immunogenic in healthy adults in India.

Official Title
-----------------
A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in India

Conditions
-----------------
Herpes Zoster, Shingles

Intervention / Treatment
-----------------
* Biological: Zoster Vaccine Live


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No fever on day of vaccination Females have a negative pregnancy test and use an acceptable method of birth control, or are postmenopausal Underlying chronic illnesses must be stable Exclusion Criteria: History of hypersensitivity reaction to any vaccine component Prior receipt of a varicella or zoster vaccine Prior history of herpes zoster Have recently had another vaccination Have recently received blood products other than autologous blood transfusion Pregnant or breast feeding Use of immunosuppressive therapy Known or suspected immune dysfunction Use of nontopical antiviral therapy with activity against herpesvirus

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Zoster Vaccine Live<br> | Biological: Zoster Vaccine Live<br>* One approximately 0.65 mL injection subcutaneously on Day 1<br>* Other names: V211;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody at 6 Weeks Postvaccination | Antibody titers were measured by VZV-specific glycoprotein enzyme-linked immunosorbent assay (gpELISA). | Prevaccination up to 6 weeks postvaccination | 
| Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers at 6 Weeks Postvaccination | GMFR was analyzed as the geometric mean of the ratio of VZV antibody titer (gpELISA units/mL) at postvaccination week 6 over VZV antibody titer (gpELISA units/mL) at prevaccination day 1. | Prevaccination up to 6 weeks postvaccination | 
| Number of Participants With Serious Adverse Events | A serious adverse event is one that results in death, is life-threatening, results in a persistent or significant disability, results in or prolongs hospitalization, results in a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an other important medical event based on medical judgment. | Up to 42 days postvaccination |